Last Update 21:6
Monday, 19 November 2018

Long-lasting HIV injection is a step closer: Study

The innovative dosing regimen could transform HIV therapy by reducing the number of days a person receives treatment from 365 to 12

Reuters , Wednesday 31 Oct 2018
Reuters
Share/Bookmark
Views: 1638
Share/Bookmark
Views: 1638

A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators.

The experimental two-drug injection of cabotegravir and rilpivirine was shown to suppress the HIV virus in a cohort of adults who had not been on a long-established daily three-drug oral regimen, GSK’s majority-owned HIV unit ViiV Healthcare said.

In the study, adults with HIV were first put on a 20-week three-drug program of daily tablets to suppress the virus before being switched to monthly injections. After 48 weeks, the injections maintained a similar rate of suppression as the pills, it said.

The results support an earlier major study, which involved adults who had been using a three-drug oral regimen to control the virus.

ViiV Healthcare’s chief medical officer John C. Pottage said the trial provided further evidence that a long-acting injection could offer an alternative to daily, oral therapy for people who had previously achieved viral suppression.

“This innovative dosing regimen could transform HIV therapy by reducing the number of days a person receives treatment from 365 to 12,” he said.

“Work on new methods of HIV treatment, including long-acting injectable therapies, supports our goal of making HIV a smaller part of the lives of people living with HIV.” 

Short link:

 

Email
 
Name
 
Comment's
Title
 
Comment
Ahram Online welcomes readers' comments on all issues covered by the site, along with any criticisms and/or corrections. Readers are asked to limit their feedback to a maximum of 1000 characters (roughly 200 words). All comments/criticisms will, however, be subject to the following code
  • We will not publish comments which contain rude or abusive language, libelous statements, slander and personal attacks against any person/s.
  • We will not publish comments which contain racist remarks or any kind of racial or religious incitement against any group of people, in Egypt or outside it.
  • We welcome criticism of our reports and articles but we will not publish personal attacks, slander or fabrications directed against our reporters and contributing writers.
  • We reserve the right to correct, when at all possible, obvious errors in spelling and grammar. However, due to time and staffing constraints such corrections will not be made across the board or on a regular basis.
Latest

© 2010 Ahram Online.